Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Koselugo(司美替尼selumetinib)

MEK inhibitors (mitogen activation inhibitors) are gradually being used in clinical applications. They can first be used to treat chronic pain, inhibit cancer cell proliferation, and treat non-small cell lung cancer. MEK inhibitors combined with nilotinib can overcome Drug resistance in chronic myelogenous leukemia (CML). Recent treatments for metastatic biliary tract cancer and control of low-grade serous ovarian or peritoneal cancer. Therefore, the MEK inhibitor selumetinib will become a new drug for the treatment of cancer.

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.